Anupam Rasayan India Ltd (NSE:ANURAS)
India · Delayed Price · Currency is INR | Market Cap | 135.87B +10.4% |
| Revenue (ttm) | 26.24B +24.6% |
| Net Income | 1.80B +19.3% |
| EPS | 17.97 +31.4% |
| Shares Out | 113.85M |
| PE Ratio | 66.41 |
| Forward PE | 37.04 |
| Dividend | 1.50 (0.13%) |
| Ex-Dividend Date | Sep 18, 2026 |
| Volume | 363,451 |
| Open | 1,197.00 |
| Previous Close | 1,191.90 |
| Day's Range | 1,184.40 - 1,210.70 |
| 52-Week Range | 1,059.10 - 1,415.00 |
| Beta | 0.14 |
| Analysts | Hold |
| Price Target | 1,263.33 (+5.86%) |
| Earnings Date | Nov 6, 2026 |
About Anupam Rasayan India
Anupam Rasayan India Ltd engages in the custom synthesis and manufacturing of specialty chemicals in India, Europe, Japan, Singapore, China, North America, and internationally. It operates through two segments, Life Science related Specialty Chemicals and Performance Material. The company offers life science related specialty chemicals, such as agro intermediates and agro active ingredients for the agrochemicals industry; anti-bacterial and ultraviolet protection intermediates and ingredients for the personal care industry; and intermediates an... [Read more]
Financial Performance
In fiscal year 2026, Anupam Rasayan India's revenue was 23.65 billion, an increase of 64.61% compared to the previous year's 14.37 billion. Earnings were 1.70 billion, an increase of 82.24%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ANURAS stock is "Hold." The 12-month stock price target is ₹1,263, which is an increase of 5.86% from the latest price.
News
Anupam Rasayan India Transcript: Q2 26/27
H1 FY27 total income rose 21% YoY and EBITDA 38%, with margins improving. Bliss GVS expands the pharma platform; H2 consolidated revenue guidance is INR 2,400–2,500 crore.
Anupam Rasayan India Quarterly report: Q2 2027
Anupam Rasayan India has published its Q2 2027 quarterly earnings report on November 6, 2026.
Anupam Rasayan India Slides: Q2 2027
Anupam Rasayan India has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on November 6, 2026.
Anupam Rasayan India Transcript: Q1 26/27
Q1 FY27 total income rose 36% YoY and EBITDA grew 35%, while PAT increased 6% amid higher depreciation. Growth plans center on new product ramps, Jayhawk and the pending Bliss acquisition; full-year EBITDA margin guidance is 22%-24% consolidated.
Anupam Rasayan India Quarterly report: Q1 2027
Anupam Rasayan India has published its Q1 2027 quarterly earnings report on August 14, 2026.
Anupam Rasayan India Slides: Q1 2027
Anupam Rasayan India has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 14, 2026.
Anupam Rasayan India commercialises ETFA using flow chemistry, a global first
Anupam Rasayan India Ltd. has announced the commercialisation of ETFA (Ethyl trifluoroacetate) production through its proprietary continuous flow chemistry platform. This marks a global first in the c...
Anupam Rasayan makes Rs 299 per share open offer for Bliss GVS Pharma
Anupam Rasayan India Limited has announced an open offer to acquire up to 2,77,26,848 fully paid-up equity shares of Bliss GVS Pharma Limited at a price of ₹299 per share.…
Bliss GVS Pharma faces Rs 299 per share open offer from Anupam Rasayan
Bliss GVS Pharma Limited is the target of an open offer from Anupam Rasayan India Limited, which seeks to acquire up to 2,77,26,848 fully paid-up equity shares. This represents 26%…
Anupam Rasayan India Transcript: Q4 25/26
FY26 revenue rose 65% to INR 2,384 crore, with INR 334 crore of operating cash flow and greater pharma and materials exposure. Growth plans center on acquisitions, pipeline commercialization and capacity utilization, while Bliss completion and integration remain key execution factors.
Anupam Rasayan India Annual report: Q4 2026
Anupam Rasayan India has published its Q4 2026 annual report on May 25, 2026.
Anupam Rasayan India Quarterly report: Q4 2026
Anupam Rasayan India has published its Q4 2026 quarterly earnings report on May 25, 2026.
Anupam Rasayan India Slides: Q4 2026
Anupam Rasayan India has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 25, 2026.
Anupam Rasayan India acquires up to 48.2% stake in Bliss GVS Pharma
Anupam Rasayan India Ltd. has announced a significant acquisition, entering into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited. The acquisition also includes ...
Anupam Rasayan India to acquire up to 48.2% stake in Bliss GVS Pharma
Anupam Rasayan India Ltd. has announced its entry into a definitive agreement to acquire a 43.3-48.2% equity stake in Bliss GVS Pharma Limited. The acquisition also includes an open offer…
Anupam Rasayan reports 65% revenue growth in FY26, driven by strategic expansions
Anupam Rasayan India Ltd., a leading player in custom synthesis and specialty chemicals, has reported a significant 65% year-on-year increase in total revenue for the financial year ending March 31,…
Anupam Rasayan announces resignation of Deputy CFO Vishal Thakkar
Anupam Rasayan India has announced the resignation of its Deputy Chief Financial Officer (CFO) and Key Managerial Personnel, Mr. Vishal Thakkar, effective immediately from May 23, 2026. The company di...
Anupam Rasayan to acquire up to 74.20% stake in Bliss GVS Pharma for Rs 1,369 crore
Anupam Rasayan India has announced its board's approval for acquiring up to 74.20% of Bliss GVS Pharma's equity shares. The acquisition will be executed through a share purchase agreement and…
Anupam Rasayan to acquire 74.20% stake in Bliss GVS Pharma for Rs 1,369 crore
Anupam Rasayan India has announced its intention to acquire a significant stake in Bliss GVS Pharma, a move designed to bolster its presence in the pharmaceutical sector. The acquisition involves…
Anupam Rasayan India Transcript: Q3 25/26
9M FY26 revenue rose 84% YoY, with growth from pharma, agro recovery, and performance materials. Jayhawk would add U.S. manufacturing and high-value market access; working-capital days are targeted below 200 in FY27.
Anupam Rasayan India Quarterly report: Q3 2026
Anupam Rasayan India has published its Q3 2026 quarterly earnings report on February 14, 2026.
Anupam Rasayan India Slides: Q3 2026
Anupam Rasayan India has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 14, 2026.
Anupam Rasayan India Transcript: Jayhawk Acquisition Presentation
The acquisition adds Jayhawk’s U.S. manufacturing, advanced chemistries and customer base, with ~$150 million in consideration and expected day-one EPS accretion. Integration will initially preserve U.S. operations, then pursue selective expansion and a dual-site supply model.
Anupam Rasayan signs definitive agreement to acquire U.S.-based Jayhawk Fine Chemicals Corporation
Anupam Rasayan India Ltd. has announced that it has signed a definitive agreement to acquire 100% equity stake in Jayhawk...
Anupam Rasayan approves acquisition of Monitchem Kansas S.à r.l and subsidiaries for up to USD 155 million
Anupam Rasayan India Ltd has announced a major overseas acquisition as its Board, in a meeting held on December 9,...